Media store

Media Releases

Published on: 14 February 2020

China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with ...

Published on: 10 February 2020

Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease

Basel, 10 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an ...

Published on: 6 February 2020

Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy

Basel, 06 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged ...

Upcoming Events

All

17March

Annual General Meeting (tentative)

(CEST)

Basel, Switzerland

add to calendar

22April

First quarter sales 2020

(CEST)

Basel

23July

Half year results 2020

(CEST)

Basel

15October

Third quarter sales 2020

(GMT)

Basel

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11